118 related articles for article (PubMed ID: 38832653)
1. Basiliximab Treatment for Patients With Steroid-Refractory Acute Graft-Versus-Host Disease Following Matched Sibling Donor Hematopoietic Stem Cell Transplantation.
Jiang XY; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Sun YQ; Mo XD; Huang XJ
Cell Transplant; 2024; 33():9636897241257568. PubMed ID: 38832653
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study.
Liu SN; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ; Mo XD
Am J Hematol; 2020 Aug; 95(8):927-936. PubMed ID: 32311156
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of basiliximab in the treatment of 87 cases of steroid-refractory or steroid-dependent acute graft-versus-host disease].
He ZX; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; He Y; Wei JL; Chen X; Jiang EL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):120-127. PubMed ID: 35381672
[No Abstract] [Full Text] [Related]
4. Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-
Shen MZ; Li JX; Zhang XH; Xu LP; Wang Y; Liu KY; Huang XJ; Hong SD; Mo XD
Front Immunol; 2021; 12():749266. PubMed ID: 34621279
[TBL] [Abstract][Full Text] [Related]
5. Basiliximab as Treatment for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients after Haploidentical Hematopoietic Stem Cell Transplantation.
Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
Biol Blood Marrow Transplant; 2020 Feb; 26(2):351-357. PubMed ID: 31704470
[TBL] [Abstract][Full Text] [Related]
6. Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis.
Mo XD; Hong SD; Zhao YL; Jiang EL; Chen J; Xu Y; Sun ZM; Zhang WJ; Liu QF; Liu DH; Wan DM; Mo WJ; Ren HY; Yang T; Huang H; Zhang X; Wang XN; Song XM; Gao SJ; Wang X; Chen Y; Xu B; Jiang M; Huang XB; Li X; Zhang HY; Wang HT; Wang Z; Niu T; Wang JS; Xia LH; Liu XD; Li F; Zhou F; Lang T; Hu J; Wu SJ; Huang XJ
Am J Hematol; 2022 Apr; 97(4):458-469. PubMed ID: 35064928
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial.
Fu H; Sun X; Lin R; Wang Y; Xuan L; Yao H; Zhang Y; Mo X; Lv M; Zheng F; Kong J; Wang F; Yan C; Han T; Chen H; Chen Y; Tang F; Sun Y; Chen Y; Xu L; Liu K; Zhang X; Liu Q; Huang X; Zhang X
BMC Med; 2024 Feb; 22(1):85. PubMed ID: 38413930
[TBL] [Abstract][Full Text] [Related]
8. Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation.
Wang JZ; Liu KY; Xu LP; Liu DH; Han W; Chen H; Chen YH; Zhang XH; Zhao T; Wang Y; Huang XJ
Transplant Proc; 2011 Jun; 43(5):1928-33. PubMed ID: 21693302
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease.
Schmidt-Hieber M; Fietz T; Knauf W; Uharek L; Hopfenmüller W; Thiel E; Blau IW
Br J Haematol; 2005 Aug; 130(4):568-74. PubMed ID: 16098072
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease].
Sun AN; Wu DP; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Fu ZZ; Ma X; Han Y; He GS; Chen SN; Xue SL; Zhao Y
Ai Zheng; 2006 Aug; 25(8):1019-22. PubMed ID: 16965686
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial.
Zhao K; Lin R; Fan Z; Chen X; Wang Y; Huang F; Xu N; Zhang X; Zhang X; Xuan L; Wang S; Lin D; Deng L; Nie D; Weng J; Li Y; Zhang X; Li Y; Xiang AP; Liu Q
J Hematol Oncol; 2022 Mar; 15(1):22. PubMed ID: 35255929
[TBL] [Abstract][Full Text] [Related]
12. [Short-term substitution of calcineurin inhibitors (CNI) with recombinant humanized anti-CD25 monoclonal antibody (Basiliximab) as aGVHD prophylaxis in CNI intolerant patients after allogeneic hematopoietic stem cell transplantation].
Shao S; Liu HX; Jiang Y; Li S; Wei DL; Zhu J; Wang C; Zhao CX
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):115-120. PubMed ID: 38604786
[No Abstract] [Full Text] [Related]
13. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
[No Abstract] [Full Text] [Related]
14. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.
Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H
Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631
[TBL] [Abstract][Full Text] [Related]
15. Myeloablative haploidentical hematopoietic stem cell transplantation using basiliximab for graft-versus-host disease prophylaxis.
Huang R; Tu S; Deng L; Kang Q; Song C; Li Y
Hematology; 2015 Jul; 20(6):313-9. PubMed ID: 25321657
[TBL] [Abstract][Full Text] [Related]
16. [Humanized anti-CD25 monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation].
Wu YX; Wu DP; Ma X; Jiang SS; Hou MJ; Jing YT; Liu B; Li Q; Wang X; Wu YB; Hu XH
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):755-761. PubMed ID: 38049320
[No Abstract] [Full Text] [Related]
17. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
[TBL] [Abstract][Full Text] [Related]
18. Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia.
Zhang R; Shi W; Wang HF; You Y; Zhong ZD; Li WM; Zhang C; Lu X; Wang YD; Zheng P; Fang J; Hong M; Wu QL; Xia LH
Bone Marrow Transplant; 2017 Sep; 52(9):1253-1260. PubMed ID: 28581464
[TBL] [Abstract][Full Text] [Related]
19. First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia.
Peinemann F; Bartel C; Grouven U
Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006407. PubMed ID: 23881658
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Hematopoietic Stem Cell Transplantation Outcomes Using Matched Sibling Donors, Haploidentical Donors, and Immunosuppressive Therapy for Patients With Acquired Aplastic Anemia.
Zhang Y; Huo J; Liu L; Shen Y; Chen J; Zhang T; Chen X; Pang A; Yang D; Zhang R; Ma Q; Zhai W; He Y; Wei J; Jiang E; Han M; Zheng Y; Feng S
Front Immunol; 2022; 13():837335. PubMed ID: 35178053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]